This paper will review evidence on the safety and efficacy of new anti
depressants in high-risk patients. Where available, data will be revie
wed on the serotonin selective reuptake inhibitors (SSRIs), including
fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and o
n the new reversible inhibitor of monoamine oxidase-A moclobemide.